Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with...
Brain
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
Study to assess efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease BOSTON, Nov. 13, 2023 (GLOBE...
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June,...
Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression
Results Suggest Formulation Potentially Suitable for At-Home Administration Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial MUNICH, Germany,...
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in...
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity...
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
Topline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) --...
The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Day
Psychedelic Science 2023 was the breakthrough conference in psychedelics over 5 days in June 2023 in Denver, CO. Hosted by...
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO),...
Nalu Medical, Inc. Ranked Number 19 Fastest Growing Company in North America in the 2023 Deloitte Technology Fast 500™
Attributes 9,623% Revenue Growth to the exceptional clinical performance and unique technology of the Nalu Neurostimulation System in treating unmet...
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF),...
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
-- Blocking of α5β1 integrin has been shown to improve motor function and increase survival in the SOD1G93A mouse model of...
My Crew Doses Inc. Announces the No Fallen Heroes Partnership and Addition of Key Strategic Investors and Advisors
Jupiter, Florida--(Newsfile Corp. - November 9, 2023) - My Crew Doses Inc., (the "Company" or "MCD"), an American PhD-led brand...
AlzeCure Publishes its Interim Report for January – September 2023
STOCKHOLM, SWEDEN / ACCESSWIRE / November 9, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced...
Neurolutions, Inc. and Kandu Health Announce Strategic Partnership to Accelerate Access to Breakthrough Brain Computer Interface (BCI) and Remote Support for Stroke Rehabilitation
Companies’ Post-Stroke Solutions Aim to Significantly Improve Recovery Journey for Patients and Their FamiliesSANTA CRUZ, Calif. & CAMPBELL, Calif.--(BUSINESS WIRE)--Neurolutions,...
GE HealthCare and Masimo Collaborate to Bring Masimo SET® Pulse Oximetry to the Wireless and Wearable GE HealthCare Portrait Mobile Platform
CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo...
As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
Company Introduces Multimedia Resources to Bring Awareness of SADLAVAL, QC / ACCESSWIRE / November 8, 2023 / As daylight saving...
NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device
CARMEL, Ind., Nov. 08, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of...
Masimo Announces New Member of the Board of Directors
Rolf A. Classon Joins Masimo’s Board of DirectorsIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been...